Inventor
GROMADA JESPER
US47 patents
⚠️ This page may combine multiple inventors who share the name “GROMADA JESPER”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
REGENERON PHARMA
46 patentsUS9718881B2Aug 1, 2017
Anti-Activin A antibodies and uses thereof
REGENERON PHARMA21 citations93
US10023644B2Jul 17, 2018
Antigen-binding proteins that activate the leptin receptor
REGENERON PHARMA14 citations92
US9644018B2May 9, 2017
Antibody modulators of APLNR
REGENERON PHARMA13 citations91
US9657099B2May 23, 2017
Anti-glucagon antibodies
REGENERON PHARMA10 citations84
US10618968B2Apr 14, 2020
Antigen-binding proteins that activate the leptin receptor
REGENERON PHARMA7 citations83
US10253102B2Apr 9, 2019
Antigen-binding proteins that activate the leptin receptor
REGENERON PHARMA7 citations83
US10961583B2Mar 30, 2021
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA9 citations82
US10787647B2Sep 29, 2020
HSD17B13 variants and uses thereof
REGENERON PHARMA10 citations81
US11608381B2Mar 21, 2023
Methods of treatment using a leptin receptor agonist antibody
REGENERON PHARMA4 citations74
US11045522B2Jun 29, 2021
Glucagon-like peptide 1 receptor agonists and uses thereof
REGENERON PHARMA3 citations73
US11535675B2Dec 27, 2022
Antigen-binding proteins that antagonize leptin receptor
REGENERON PHARMA2 citations72
US10947310B2Mar 16, 2021
Fusion protein comprising apelin and an anti-APLNR antibody
REGENERON PHARMA1 citations72
US10626173B2Apr 21, 2020
Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR
REGENERON PHARMA2 citations72
US10550192B2Feb 4, 2020
Antigen-binding proteins that antagonize leptin receptor
REGENERON PHARMA4 citations72
US10526403B2Jan 7, 2020
Anti-activin A antibodies and uses thereof
REGENERON PHARMA4 citations72
US10259870B2Apr 16, 2019
Anti-ANGPTL8 antibodies and uses thereof
REGENERON PHARMA2 citations72
US10189901B2Jan 29, 2019
Methods for improving cardiac function by administering an antibody that activates APLNR
REGENERON PHARMA2 citations72
US10155811B2Dec 18, 2018
APLNR modulators and uses thereof
REGENERON PHARMA2 citations72
US11845963B2Dec 19, 2023
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations71
US11753628B2Sep 12, 2023
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations71
US11702700B2Jul 18, 2023
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA4 citations71
US11180757B1Nov 23, 2021
17β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
REGENERON PHARMA3 citations71
US11485958B2Nov 1, 2022
HSD17B13 variants and uses thereof
REGENERON PHARMA1 citations70
US11306148B2Apr 19, 2022
Anti-NPR1 antibodies and uses thereof
REGENERON PHARMA3 citations69
US11820826B2Nov 21, 2023
Anti-NPR1 antibodies and uses thereof
REGENERON PHARMA2 citations68
US12371503B2Jul 29, 2025
Methods of treatment using a leptin receptor agonist antibody
REGENERON PHARMA0 citations62
US12275792B2Apr 15, 2025
Antigen-binding proteins that activate the leptin receptor
REGENERON PHARMA0 citations62
US12139546B2Nov 12, 2024
Methods of treating urea cycle disorders by interfering with glucagon receptor signaling
REGENERON PHARMA0 citations62
US12090193B2Sep 17, 2024
Glucagon-like peptide 1 receptor agonists and uses thereof
REGENERON PHARMA0 citations62
US11834500B2Dec 5, 2023
Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
REGENERON PHARMA1 citations62
US10442856B2Oct 15, 2019
Methods of treating obesity with anti-ANGPTL8 antibodies
REGENERON PHARMA1 citations62
US12497460B2Dec 16, 2025
Anti-MSR1 antibodies and methods of use thereof
REGENERON PHARMA0 citations61
US12359201B2Jul 15, 2025
17ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereof
REGENERON PHARMA0 citations61
US11730150B2Aug 22, 2023
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
REGENERON PHARMA0 citations61
US11642390B2May 9, 2023
Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody
REGENERON PHARMA0 citations61
US11377502B2Jul 5, 2022
Anti-MSR1 antibodies and methods of use thereof
REGENERON PHARMA1 citations61
US10548302B2Feb 4, 2020
Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy
REGENERON PHARMA1 citations61
US12286677B2Apr 29, 2025
Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
REGENERON PHARMA0 citations59
US11708416B2Jul 25, 2023
Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
REGENERON PHARMA0 citations58
US10995146B2May 4, 2021
Methods of treating severe insulin resistance by interfering with glucagon receptor signaling
REGENERON PHARMA0 citations58
US11479802B2Oct 25, 2022
Assays for screening activity of modulators of members of the hydroxy steroid (17-beta) dehydrogenase (HSD17B) family
REGENERON PHARMA1 citations57
US12281173B2Apr 22, 2025
Methods for treating patients with hyperlipidemia by administering a PCSK9 inhibitor in combination with an ANGPTL3 inhibitor
REGENERON PHARMA0 citations52
US11977081B2May 7, 2024
ANGPTL8 assay and uses thereof
REGENERON PHARMA0 citations52
US12371475B2Jul 29, 2025
Nucleic acids encoding anchor modified antibodies and uses thereof
REGENERON PHARMA0 citations51
US10582702B2Mar 10, 2020
Non-human animals having an engineered ANGPTL8 gene
REGENERON PHARMA0 citations51
US10519240B2Dec 31, 2019
Anti-FGFR1c antibody-FGF21 fusion proteins
REGENERON PHARMA0 citations37